Dan Bloomfield, MD

Dr Bloomfield is the chief medical officer at Anthos Therapeutics and have more than 20 years of experience in drug development.

Articles by Dan Bloomfield, MD

Abelacimab Shows Potential to Shift the Standard of Care in AFib

ByKyle Munz,Christian Ruff, MD,Dan Bloomfield, MD

February 11th 2025

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

Atrial fibrillation | image credit: Uladzlislau - stock.adobe.com

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

ByKyle Munz,Christian Ruff, MD,Dan Bloomfield, MD

January 22nd 2025

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).

Latest Updated Articles

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial
Published: January 22nd 2025 | Updated:

Dan Bloomfield, MD

Articles by Dan Bloomfield, MD

Abelacimab Shows Potential to Shift the Standard of Care in AFib

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

Latest Updated Articles

Trending on AJMC

First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC

Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability

Physical Activity, Vaccination May Protect Against Long COVID

In Its 50th Year, ESMO Comes to Berlin, a City Transformed

Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations